JUL 10, 2019 05:52 PM PDT

New anticancer agent discovered

A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent that targets the MYC gene, which is overexpressed in cancer and is associated with almost every process of the disease. While scientists have known for decades the MYC oncogene is behind most types of cancer, is continues to be difficult to regulate; the finding of these MYC promoter G-quadruplex stabilizers could, therefore, have significant implications for how we treat cancer patients.

The research was supported by the National Cancer Institute and the National Institutes of Health and has the potential to aid in treating almost every kind of cancer, according to the authors.

"We are striving to discover effective anticancer agents," said Mark Cushman, one of the leaders of the research team. "The ability to incorporate MYC promoter G-quadruplex stabilizing activity into existing topoisomerase I inhibitors has shown promise in making them more potent as anticancer agents and in making cancer cells less likely to become resistant to them."

The anticancer agents that the team discovered are called indenoisoquinoline MYC promoter G-quadruplex stabilizers. In addition to their effects on MYC, some of these agents also are able to inhibit topoisomerase I, an enzyme produced in greater amounts in cancer cells that facilitates DNA replication.

Researchers have found new anticancer agents to downregulate the MYC gene. Photo: Pixabay

This discovery with MYC will also help aid in several current ongoing clinical trials that are testing three other anticancer agents found by Cushman and his team in the past.

"Targeting promoter G-quadruplexes offers a relatively new and exciting strategy to inhibit the critical oncogene expression in cancer cells," said Danzhou Yang, who led the research with Cushman. "We hope to combine the potency of the DNA-targeted drugs and selectivity of molecular-targeted approaches for new cancer therapeutics."

Sources: Science Daily, Journal of the American Chemical Society

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 24, 2019
Cell & Molecular Biology
JUL 24, 2019
Researchers Use Urine Cells to Create Kidney Organoids
These organoids be used for research and can be made from patient samples, as way to personalize the treatment....
JUL 24, 2019
Cancer
JUL 24, 2019
Low-fat diets in women can reduce mortality rates of breast cancer
Results from an almost thirty-year clinical trial regarding women’s nutritional health and breast cancer were announced recently and will be presente...
JUL 24, 2019
Drug Discovery
JUL 24, 2019
How a Cancer Drug Inhibits DNA Repair in Cancer Cells
In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow...
JUL 24, 2019
Drug Discovery
JUL 24, 2019
Injectable Hydrogel Recruits Chemotherapeutics to Tumor Site
Targeting tumor cells while avoiding harming healthy tissue remains a growing central challenge in the field of chemotherapeutics. For a while, scientists ...
JUL 24, 2019
Cancer
JUL 24, 2019
Self-Destructing Cancer: Study Stops Chain Reaction of Tumor Growth
A new study reveals that stopping one protein from functioning can cause some cancer cells to die from stress....
JUL 24, 2019
Cancer
JUL 24, 2019
Why some cancers receive more research funding
In a new study from Northwestern Medicine, researchers analyzed which types of cancer receive the most and least amounts of research funding. Their results...
Loading Comments...